WebsiteGear Logo Log In
New User? Sign Up
About | Contact | FAQ
  Home News Website Related Online Marketing Saturday, January 19, 2019 
Add Press Release News | News Feeds Feeds | Email This News Email

M&A Activities in the Pharma Contract Manufacturing Industry, 2015-2017 - 130 Acquisitions of Service Providers, 2018 Report
Friday, January 11, 2019

DUBLIN, Jan. 11, 2019 /PRNewswire/ --

The "PharmSource - M&A in the Contract Manufacturing Industry: Implications and Outlook - 2018 Edition" report has been added to's offering.

"PharmSource - M&A in the Contract Manufacturing Industry: Implications and Outlook - 2018 Edition" analyzes merger and acquisition (M&A) activity in the pharmaceutical contract manufacturing industry during the period 2015-2017. The services considered in this report are contract manufacturing of active pharmaceutical ingredients (APIs) and finished dose products, associated analytical services, and packaging. Contract research providers were excluded.

Mergers and Acquisitions of companies and facilities have been a high profile feature of the pharmaceutical CMO industry in current times. Acquisition deals consistently receive high profile coverage in industry news media, with questions surrounding valuations, strategic intent and which companies are potentially next targets continuously debated in the industry.

There were 130 acquisitions of service providers during the three-year period from 2015-2017. The majority of acquisitions targeted contract manufacturing organizations (CMOs) that focused on APIs-small molecule, dose, and analytical services. Nearly 70% of acquirers of services companies were strategic acquirers, that is, they were operating companies rather than investment firms. A few services companies changed hands as a consequence of the purchase of their parent company, while several CMOs were acquired by bio/pharma companies seeking to secure product supply.

More than half of acquirers were public companies, although 36% of company acquisitions were by PE firms or by CMOs owned by PE firms, with a high level of influence on the industry. Companies with complex technologies, including biologics manufacturing, are likely to be sought-after targets, as well as CMOs with specialized capabilities. However, in the coming years, M&A activity will be hindered by higher interest rates, uncertain trade and investment policies, high valuation expectations, and sizeable debt loads carried by some of the most active acquirers.


    --  Helps bio/pharmaceutical manufacturing, development, and supply chain
        executives understand the implications of M&A activity on their supply
        base and sourcing options.
    --  Helps executives at CMOs and associated contract services companies and
        investors to recognize the significance of M&A activities for the
        competitive dynamics of the industry and how company strategies must
        change to address the altering market.
    --  To gain insights that might enable predictions of the nature and
        implications of M&A activity in the next three to five years.

Reasons to Buy

    --  CMOs: market trends, strategic planning, competitive intelligence,
        performance benchmarking
    --  Bio/Pharma: supplier performance benchmarking, market trends,
        competitive intelligence
    --  Private equity and Stock analysts: target identification and analysis,
        portfolio company performance benchmarking.

Key Topics Covered:

1. Executive Summary

2 Objectives and Methodology

3 Overview of M&A Activity 2015-2017
Target Characteristics
Acquirer Characteristics

4 Segment Close-Ups of M&A Activity, 2015-2017
Dose Manufacturing
API - Biologic
API - Small Molecule
Analytical Services
Formulation and Clinical Supplies Manufacturing

5 Valuations

6 Facility Acquisitions

7 What It Means

8 The Outlook for M&A in the Manufacturing Services Industry

9 Notes on Methodology

10 Appendix
Service Acquisitions 2015-2017
Primary Research - Key Opinion Leaders Cited in this Report

Companies Mentioned

    --  3SBio
    --  ABC Laboratories
    --  Absorption Systems
    --  Abzena
    --  Acacia Lifesciences
    --  Accucaps
    --  Accuratus Lab Services
    --  Advanced BioScience Laboratories
    --  Advantar Laboratories
    --  Aeras
    --  Agere Pharmaceuticals
    --  AGIC Capital
    --  Ajinomoto
    --  Akorn

For more information about this report visit

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:

SOURCE Research and Markets

Email This News Email | Submit To Slashdot Slashdot | Submit To Digg | Submit To | News Feeds Feeds

Nav Preeminent Realtor Tracy King Provides Comprehensive and Exclusive Resources for LA Homebuyers and Sellers | Jan 19, 2019
Nav Grey New York Chosen As Agency Of Record For Douglas Elliman Real Estate | Jan 18, 2019
Nav transcosmos Expands and Relocates "MC Naha Center," Which Offers Digital Marketing Services | Jan 18, 2019
Nav Real Estate Investor Michael Blank Identifies 3 Stock Market Alternatives for 2019 | Jan 18, 2019
Nav The Conference Board Leading Economic Index┬« (LEI) for Mexico Declined | Jan 18, 2019
Nav $92.87 Billion Integrated Food Ingredients Market - Global Outlook & Forecasts 2017-2026 | Jan 18, 2019
Nav Cancer Modelling Company Physiomics in the News | Jan 18, 2019
Nav Global Self-Publishing Platform PublishDrive Releases Case Study on how their Groundbreaking Pricing Maximizes Author Profits | Jan 18, 2019
Nav 2018 $6.5 Bn Surgical Site Infection Control Market - Global Forecast to 2026 | Jan 18, 2019
Nav Internet Marketing Company, fishbat, Offers 5 Tips to Perfect Your Restaurant's Social Media Pages | Jan 18, 2019

Submit News | View More News View More News